1 / 4

Practical considerations : antidote for dabigatran

Practical considerations : antidote for dabigatran. Dabigatran antidote: rationale. The ability to reverse anticoagulation is important in patients who: Require emergency procedures Have taken an overdose

mara-randolph
Télécharger la présentation

Practical considerations : antidote for dabigatran

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Practical considerations : antidote for dabigatran

  2. Dabigatran antidote: rationale • The ability to reverse anticoagulation is important in patients who: • Require emergency procedures • Have taken an overdose • To address this, monoclonal antibodies designed to neutralize the activity of dabigatran were generated • Engineered to reduce immunogenicity and maintain activity • Lead candidates were tested for their ability to reverse the anticoagulant effect of dabigatran in human plasma in vitro and in rats ex vivo (diluted thrombin time) 2 van Ryn et al. ACC 2011; abstract 1142–367

  3. Dabigatran antidote: results • Antibody clone 22 demonstrated the following properties: • Highly potent and specific binding to dabigatran (Kd 30 pM) • Binding correlated with complete inhibition of dabigatran anticoagulant activity, both in human plasma and whole blood, with an IC50 of 2–5 nM • Complete inhibition of anticoagulant activity of dabigatran in ex vivo studies Kd = dissociation constant; IC50 = half maximal inhibitory concentration 3 van Ryn et al. ACC 2011; abstract 1142–367

  4. Dabigatran antidote: conclusions • The engineered antibody clone 22 showed potent and selective reversal of dabigatran anticoagulation, without affecting normal haemostasis • Clone 22 is currently under further development for use in the clinic • May allow rapid and specific reversal of dabigatran where required in the future 4 van Ryn et al. ACC 2011; abstract 1142–367

More Related